# Study of ALK-001 on the Progression of Stargardt Disease

> **NCT07419334** · PHASE3 · RECRUITING · sponsor: **Alkeus Pharmaceuticals, Inc.** · enrollment: 230 (estimated)

## Conditions studied

- Stargardt Disease

## Interventions

- **DRUG:** ALK-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07419334
- **Lead sponsor:** Alkeus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-10
- **Final completion:** 2030-12
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07419334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07419334, "Study of ALK-001 on the Progression of Stargardt Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07419334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*